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Abstract: We retrospectively analyzed the outcomes of hematopoi-
etic stem cell transplantation in 7 patients with primary immunode-
ﬁciency diseases treated at the National University Hospital,
Singapore, over the period from December 1996 to January 2010.
The primary immunodeﬁciency diseases managed were X-linked
hyperimmunoglobulin M syndrome (n ¼ 3), severe combined
immunodeﬁciency (n ¼ 1), leukocyte adhesion deﬁciency type 1
(n ¼ 1), chronic granulomatous disease (n ¼ 1), and Wiskott–
Aldrich syndrome (n ¼ 1). The age of the patients ranged from
5 months to 17 years. Conditioning regimen depended on the type
of immunodeﬁciency, whereas supportive treatment was tailored for
differing pretransplant conditions. Eight stem cell transplantations
were performed for 7 patients. Donors were HLA-matched sibling
donors for 2 patients and unrelated donors for the rest. At the median
follow-up of 8.6 years (range 2.2–15.0 years) as of December 2011,
6 patients were alive and cured of their primary diseases.
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Stem cell transplantation (SCT) is the curative treatmentfor severe primary immunodeﬁciency diseases (PIDs). If
left untreated, severe PIDs are associated with high mortality
risk and poor quality of life from serious infections in child-
hood. Overall survival rates for matched-related donor trans-
plants ranged from 69 to 100% depending on the underlying
disease type and promptness of the transplant.1–3 For matched-
unrelated donor transplants, the increase in the donor pool
together with improvements in supportive care and novel con-
ditioning regimens to reduce risks of graft-versus-host disease
(GVHD) has resulted in overall survival to up to 81%.1,4 In
addition, early transplantation before the development of seri-
ous infections has proven beneﬁcial.1–6 In our center, we have
performed SCT for the following PIDs: hyperimmunoglobulin M
(HIgM) syndrome, severe combined immunodeﬁciency
(SCID), leukocyte adhesion deﬁciency type 1 (LAD1),
chronic granulomatous disease (CGD), and Wiskott–Aldrich
syndrome. This article aims to describe the experience over
the period from 1996 to 2008 in treating 7 children with PIDs
at the National University Hospital, Singapore.
METHODS
This was a retrospective study of 7 patients with PID
who underwent SCT at Singapore’s University Children’s
Medical Institute, National University Health System, from
December 1996 to January 2010 (Table 1). There were 8
SCTs, which took place for these 7 patients, as 1 patient
required a second transplant. All the SCTs for PIDs that
had been performed in our center were included in this study
description. We traced the patient ﬁles to determine the events
pre-SCT and to assess survival rate and event-free survival
after SCT. Ethics approval was obtained from the Institutional
Review Board of the National University Hospital.
Stem Cell Transplants and Conditioning
Two SCTs were HLA-matched, sibling donor transplants
(1 bone marrow and 1 peripheral blood), 3 patients underwent
unrelated transplants, which were fully HLA-matched at the
antigen level (1 peripheral blood, 1 bone marrow, and 1 cord
blood), and 3 patients had cord blood unrelated transplants,
which were HLA-matched at 4 or 5 (out of 6) antigens (Table 2).
Except for patient 3, busulfan was used in all regimens
in combination with cyclophosphamide, ﬂudarabine, and
antithymocyte globulin (rabbit). Only the patient with SCID
(patient 3) underwent a reduced intensity preconditioning
regimen comprising cyclophosphamide and ﬂudarabine. All
patients received GVHD prophylaxis with cyclosporine A
and/or a combination of short-course methotrexate, methyl-
prednisolone, and mycophenolate mofetil. The median total
nucleated cell dose was 22.0 · 107 per kilogram (range, 4.78–
46.9 · 107/kg), whereas the median CD34 cell dose was
2.62 · 106 per kilogram (range, 0.15–5.54 · 106/kg) (Table 2).
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Supportive Treatment
Bacterial prophylaxis comprised oral bactrim until
day 22 of SCT, which was restarted when the absolute neu-
trophil count was .1 · 109/L. Antifungal prophylaxis com-
prised oral itraconazole solution for all patients. Weekly
intravenous immunoglobulin (from day 25 to day 184 of
SCT) was given for antiviral prophylaxis. Acyclovir was
given to patients who were seropositive for herpes viruses.
Other supportive therapy included granulocyte colony-stimu-
lating factor.
Engraftment
Myeloid engraftment was taken as the ﬁrst of 3 con-
secutive days with absolute neutrophil count.0.5 · 109/L, red
cell engraftment as the ﬁrst of 7 days without transfusions,
and platelet engraftment as the day when platelet count was
.50 · 109/L without transfusions for 7 days prior.
RESULTS
The PIDs managed were X-linked HIgM syndrome
(n ¼ 3), SCID (n ¼ 1), LAD1 (n ¼ 1), CGD (n ¼ 1), and
Wiskott–Aldrich syndrome (n ¼ 1) (Table 1). Genetic studies
were done for all patients except patient 1 for whom it was
not available. For patient 2 (CGD), chorionic villus sampling
was done for the brotherdmutation in the gp91-phox gene
located on chromosome X (Xp21.1). Tissue sample of patient
3 (X-linked SCID) could not be genetically typed; however,
the mother was heterozygous for a deleterious splice mutation
at complementary DNA (cDNA) 868 in the IL2RG gene
[cDNA mutation, 868(15) splice del ga]. Patient 4 (HIgM
syndrome) had an X-linked insertion deletion (indel) mutation





Diagnosis (mo) Complications Before SCT
1 M WAS 3 d 52 CMV retinitis and colitis, infectious chronic diarrhea with rectal prolapse,
hypoalbuminemia, iron deﬁciency anemia, failure to thrive
2 M CGD 4 mo 12 Intra-abdominal sepsis, right elbow subcutaneous abscess (Pseudomonas
ﬂuorescens), oral candidiasis, failure to thrive
3 M X-linked SCID 13 d 4 Systemic CMV disease (hepatitis, colitis, retinitis), chronic diarrhea, tinea,
oral thrush
4 M X-linked HIgM/CD40
ligand deﬁciency
12 mo 68 Bronchiectasis and recurrent lung infections, Pneumocystis jiroveci pneumonitis,
chronic diarrhea, pin worm infestations, chicken pox
5 M LAD1 4 mo 26 Tracheostomy (laryngotracheoesophageal cleft type 2), bilateral aspiration
pneumonia, left lower lobe abscess, skin ulcers, hiatus hernia with severe
gastro-oesophageal reﬂux disease, gastrostomy site wound breakdown,
hypertension, iron deﬁciency anemia, hypoalbuminemia, failure to thrive
6 M X-linked HIgM/CD40
ligand deﬁciency
3 mo 22 Pneumonia, recurrent upper respiratory tract infection, Salmonella septicemia
and enteritis, gastroenteritis, failure to thrive
7 M X-linked HIgM/CD40
ligand deﬁciency
27 mo 44 Recurrent bronchitis, gastroenteritis, allergic rhinitis
WAS, Wiskott–Aldrich syndrome.

















1 56 4 BM MRD 6/6 BU 16.0 mg/kg; CY 200 mg/kg CsA 1 MTX 23.7 4.8
2 20 8 PB MRD 6/6 BU 16.0 mg/kg; CY 200 mg/kg CsA 1 MTX 22.1 5.54
3 5 1 CB MUD 6/6 CY 100 mg/kg; FLU 150 mg/m2 CsA 1 MTX 10.1 2.43
4 204 136 CB MUD 5/6 BU 12.8 mg/kg; FLU 150 mg/m2;
ATG 8 mg/kg
CsA 1 Pred 1
MMF
4.78 0.15
5 32 6 CB MUD 4/6 BU 8.0 mg/kg; ATG 6.0 mg/kg CsA 1 Pred 21.8 0.44
6 71 49 CB MUD 5/6 BU 16 mg/kg; CY 200 mg/kg;
ATG 4.5 mg/kg
CsA 1 MTX 1
Pred
6.36 0.24
7 (ﬁrst SCT) 97 53 PB MUD 6/6 BU 16 mg/kg; CY 200 mg/kg;
ATG 5 mg/kg





100 55 BM MUD 6/6 CY 50 mg/kg; ATGequine 90 mg/kg;
rituximab 375 mg/m2
CSA 1 Pred 1
MMF
46.9 2.81
ATG, antithymocyte globulin (rabbit; thymoglobuline); BM, bone marrow; BU, busulfan; CsA, cyclosporine A; CY, cyclophosphamide; FLU, ﬂudarabine; CB, cord blood;
MRD, matched related donor; MUD, matched unrelated donor; MTX, methotrexate; PB, peripheral blood; Pred, Methylprednisolone.
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in exon 3 on the CD40 ligand gene (cDNA mutation, 347-
355delTATAATGTTinsG). Patient 5 (LAD1) had a 2490
base pair deletion on intron 8, exon 9, and intron 9 of the
CD18 gene located on chromosome 21q22.3. Patient 6 and 7
(HIgM syndrome) are brothers and have the same X-linked
deletion mutation on exon 5 in the CD40 ligand gene (“TA”
del at nucleotide positions 775-776, 775-776delTA).
PIDs were diagnosed 4 to 56 months after presentation
(median, 18 months), with the SCT performed at a median of
28.5 months after diagnosis (range, 0.7–135 months). The
median age at SCT was 63.5 months (range, 5–204 months).
Median time to myeloid engraftment was 17.5 days (range,
30–75 days). Median time to red cell engraftment was 25
days (range, 10–31 days). Median time to platelet engraftment
was 41.5 days (range, 12–145 days) (Table 3).
Of the 7 patients, there was 1 death (patient 5) after
SCT. Pre-SCT morbidity for patient 5 was considerable. He
was in poor nutritional state and suffered multiple infections
and required a tracheostomy for upper airway obstruction.
Post-SCT, he primarily experienced acute respiratory distress
syndrome secondary to parainﬂuenza type 3 and Pseudomonas
pneumonia as well as Escherichia coli sepsis, renal impair-
ment requiring hemodialysis, and gastrointestinal bleed sec-
ondary to refractory thrombocytopenia. He underwent a cord
blood unrelated transplant matched at 4 of 6 loci at the antigen
level but failed to engraft.
For the surviving patients, all except one had sustained
engraftment. Patient 7 had his ﬁrst graft rejected before
platelet engraftment was achieved. The second transplant
using the same donor for this patient was successful, with
platelet engraftment occurring after 145 days. GVHD pro-
phylaxis was modiﬁed by replacing methotrexate with
mycophenolate mofetil. The conditioning regimen for the
second transplant, performed 57 days after the ﬁrst transplant,
was with cyclophosphamide 50 mg/kg, antithymocyte glob-
ulin 90 mg/kg, and rituximab 375 mg/m2 (Table 2).
Only 1 patient was reported to have GVHD (grade I)
after transplant. Two patients had reactivated cytomegaloviral
(CMV) infections. Patient 1, who entered transplant with
CMV retinitis and colitis, received foscarnet and CMV
hyperimmune globulin, although this was limited by second-
ary renal impairment. Patient 3, who also had CMV retinitis
and hepatitis before transplant, received daily intravenous
immunoglobulin and gancyclovir before transplant and
foscarnet after transplant. Other posttransplant infections
included lung infections from a variety of causes including
Pseudomonas, Aspergillus, parainﬂuenza, and fungi.
Follow-up and Outcome
Patients were followed up at a median time of 8.6 years
(range, 2.2–15.0 years) based on the last follow-up (Table 3).










Time (Yr) From SCT to Last
Date of Follow-up
1 208 17 18 35 15.0
2 30 11 10 28 10.3
3 105 14 14 12 9.8
4 76 41 31 75 7.5
5 * 17 * * *
6 36 22 31 48 2.2
7 45 19 27 † †
7 (second SCT) 113 18 25 145 3.4
Median (range) 76 (30–75) 17.5 (11–41) 25 (10–31) 41.5 (12–145) 8.6 (2.2–15.0)
*Patient demised.
†Patient rejection and re-transplantation.
TABLE 4. Summary of Chimerism Studies Demonstrating Donor Engraftment
No. Days After SCT
Donor Mononuclear Cells (%) Donor Granulocytes (%)
IgG Levels (g/dL)
Day 21 6 mo 1 yr 2 yr Day 21 6 mo 1 yr 2 yr 1 yr
Patient 1 * * * * * * * * †
Patient 2 * * * * * * * * †
Patient 3 12.5% 75% 75% 75% 12.5% 25% 5% 12.50% 4.95
Patient 4 70% 90% 95% 95% 70% 100% 100% 100% 2.27
Patient 5 ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡
Patient 6 89% 91% 93% 96% d 96% 95% 96% 5.88
Patient 7 (second transplant) 100% 100% 100% 100% 99% 100% 100% 100% 11.28
*Studies not available at these time points (transplanted more than 10 years ago).
†IgG levels not relevant to the patient’s immunodeﬁciency disease type.
‡Patient demised.
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All surviving patients were well, infection free, and leading
a good quality of life. One patient had been discharged from
follow-up 15 years post-SCT. Chimerism studies demon-
strated donor engraftment at 21 days, 6 months, 1 year, and
2 years after SCT (Table 4). None of the surviving patients
required immunological replacement 1 year after SCT, and all
had been given hepatitis B and measles, mumps, and rubella
vaccinations with good response in speciﬁc IgG levels 2 years
after SCT. IgG levels measured at 1 year from SCT for those
with HIgM syndrome and SCID improved from pretransplant
(Table 4). For patient 2 with CGD, the nitroblue tetrazolium
test also improved from 6% (pretransplant) to 50% (22 days
after transplant). Patient 4, 6, and 7 with HIgM syndrome
secondary to CD40 ligand deﬁciency, and there were
increased CD40 ligand levels after SCT (Fig. 1).
DISCUSSION
Although SCTs have been considered the deﬁnitive
treatment for PIDs, studies continue to be performed to
demonstrate efﬁcacy and determine what factors may improve
survivability. Advances in conditioning regimens have
allowed the survivability rates for matched related donor
and matched unrelated donor to be almost on par, 69 to
100% compared with 42 to 81%, respectively. The survival
improved with earlier timing of the transplant and varied with
the type of PID being treated (SCID having a higher
survivability compared with other PIDs).1,7
Although it has been demonstrated by Buckley2 that
overall survival for SCTs improves greatly if performed
before the patient is 3.5 months old for patients with SCID,
most studies have been unable to perform a SCT within that
time frame.6,8,9 Our center was no exception with 1 patient
diagnosed with SCID at 4 months and entering transplant at
5 months of age. Patients with other PIDs were transplanted at
a median age of 63.5 months (range, 5–204 months). Our
median age for diagnosis was also quite late, at a median of
35 months (range, 4–68 months). Consequently, we had
a high rate (4 of 7 patients) for pulmonary infections pretrans-
plant among our patients, a factor associated with reduced
survival. Although our patient numbers were small, we had
1 fatality out of 7 subjects who had signiﬁcant infections
before transplant. This further emphasizes the need for early
diagnosis of PIDs and early transplantation for improved
outcomes.
CONCLUSIONS
Our small series of patients adds to the experience
of others and demonstrates the importance of SCT in severe
PIDs as a curative strategy. Despite signiﬁcant pre-SCT
morbidity from the underlying PID in our patients (eg,
systemic CMV infection, pneumonias, and bronchiectasis),
the outcome of our patients, with the exception of 1 death,
was satisfactory.
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FIGURE 1. CD40 ligand expression (percentage positive on
stimulated CD3 cells) in patients with HIgM syndrome (CD40
ligand deficiency).
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